Free Newsletter
Osiris hits milestone with stem cell trial
Osiris Therapeutics has hit a notable milestone, completing enrollment for a late-stage stem cell trial. Researchers will explore the benefits of Prochymal for steroid-refractory acute Graft versus Host Disease, a complication of bone marrow transplantation. "Completion of this study's enrollment represents an outstanding accomplishment for the transplantation field," said Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center, professor at the University of Washington and lead investigator for the trial. "Steroid-refractory acute Graft versus Host disease poses one of the most serious and difficult-to-treat complications that can occur after bone marrow transplantation. Previous studies have not identified reliably effective treatments, and no drugs have been approved for this devastating disease."
- read the press release
Related Articles:
Osiris shares soar on $1.38B Genzyme pact
Osiris inks $224M contract
Osiris shares jump on therapy results (Nov 2007)
Upstart biotech attracts A-list investors (Oct 2007)
Comments
By Jeong Chun phuoc | Posted 7:49am | December 24, 2008
"Cocktail Treatment for 'steroid-refractory acute Graft versus Host Disease'"
25.12.2008
I reckon that there will not be any significant break through medical innovation in the nearest future to tackle 'steroid-refractory acute Graft versus Host Disease' (SR disease) which is a complex phenomenon brought about by bone marrow transplantation.
As there is currently no known treatments that could be used to effectively treat SR Disease, there is a need to develop what I term as a cocktail treatment('CT treatment')consisting of a combination of all known effective treatment that may very well worked well for a specified number of patients who may response positively to the CT treatment.
Currently, no one, according to scientific literature, has carried out this kind of proposed CT treatment. Perhaps, it is high time to embark on a test trial to ascertain all real positive result from the CT treatment.
Jeong Chun Phuoc
Lecturer-in-law
Jeongphu@yahoo.com
SHARE
WITH: